Market Spotlight: Irritable Bowel Syndrome (IBS)
Market Spotlight: Irritable Bowel Syndrome (IBS)
$1,318.00
This Market Spotlight report covers the Irritable Bowel Syndrome (IBS) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, a 10-year disease prevalence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Irritable Bowel Syndrome (IBS) market, comprising key marketed and pipeline drugs, clinical trials, licensing and asset acquisition deals, recent events and analyst opinion, a 10-year disease prevalence forecast, and probability of success, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2021, there were approximately 730.1 million prevalent cases of irritable bowel syndrome (IBS) in those aged 15 years and over worldwide, and forecasts that number to increase to 785.7 million prevalent cases by 2028.
- The approved drugs in the IBS space target chloride channel 2, calcium channel, sodium-hydrogen exchanger 3, serotonin 5- HT3 receptor, guanylyl cyclase c receptor, opioid receptors, gram-negative bacteria, RNA polymerase, and serotonin 5-HT4 receptor. These drugs are administered via the oral route.
- The majority of industry-sponsored drugs in active clinical development for IBS are in Phase II.
- Therapies in development for IBS focus on a wide variety of targets. All of the pipeline drugs are administered via the oral route. The overall likelihood of approval of a Phase I gastroenterology (non inflammatory bowel disease)-other asset is 14.1%, and the average probability a drug advances from Phase III is 59%. Drugs, on average, take 10.3 years from Phase I to approval, compared to 10.1 years in the overall gastroenterology (non inflammatory bowel disease) space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for IBS have been in the early and midphases of development, with 62% of trials in Phase I–II, and only 38% in Phase III–IV.
- The US has a substantial lead in the number of IBS clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the IBS space is dominated by completed trials. AbbVie has the highest number of completed clinical trials for IBS, with 24 trials.
- AbbVie leads industry sponsors with the highest overall number of clinical trials for IBS, followed by GlaxoSmithKline
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
9 TREATMENT
9 Laxatives
9 Antidiarrheal drugs
9 Antispasmodics
9 Antidepressants
9 Serotonin receptor agonists
10 Chloride channel activators
10 Guanylyl cyclase C agonists
10 Antibiotics
10 Opioid receptors
10 Probiotics
12 EPIDEMIOLOGY
18 MARKETED DRUGS
21 PIPELINE DRUGS
26 RECENT EVENTS AND ANALYST OPINION
26 ORP-101 for IBS (January 4, 2022)
27 GSK3352589 for IBS (June 3, 2021)
29 Gemtesa for IBS (November 24, 2020)
31 Blautix for IBS (October 7, 2020)
32 SYN-010 for IBS (October 2, 2020)
34 PROBABILITY OF SUCCESS
35 LICENSING AND ASSET ACQUISITION DEALS
35 France’s Mayoly Spindler Set To Acquire Ipsen’s Consumer Business
36 REVENUE OPPORTUNITY
38 CLINICAL TRIAL LANDSCAPE
39 Sponsors by status
40 Sponsors by phase
42 BIBLIOGRAPHY
44 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in prevalent cases of IBS, 2019–28
17 Figure 2: Prevalent cases of IBS, by age group, 2019
21 Figure 3: Overview of pipeline drugs for IBS in the US
21 Figure 4: Pipeline drugs for IBS, by company
22 Figure 5: Pipeline drugs for IBS, by drug type
22 Figure 6: Pipeline drugs for IBS, by classification
27 Figure 7: ORP-101 for IBS (January 4, 2022): Phase II – PREVAIL
29 Figure 8: GSK3352589 for IBS (June 3, 2021): Phase IIa – 201 (Diarrhea-predominant)
31 Figure 9: Gemtesa for IBS (November 24, 2020): Phase IIa – URO-901-2001
32 Figure 10: Blautix for IBS (October 7, 2020): Phase II – BHT-II-002
34 Figure 11: Probability of success in the gastroenterology (non inflammatory bowel disease)-other pipeline
38 Figure 12: Clinical trials in IBS
38 Figure 13: Top 10 drugs for clinical trials in IBS
39 Figure 14: Top 10 companies for clinical trials in IBS
39 Figure 15: Trial locations in IBS
40 Figure 16: IBS trials status
41 Figure 17: IBS trials sponsors, by phase
LIST OF TABLES
13 Table 1: Prevalent cases of IBS, 2019–28
15 Table 2: Prevalent cases of IBS, by gender, 2019
16 Table 3: Prevalence of IBS, by gender, 2019
19 Table 4: Marketed drugs for IBS
23 Table 5: Pipeline drugs for IBS in the US
26 Table 6: ORP-101 for IBS (January 4, 2022)
28 Table 7: GSK3352589 for IBS (June 3, 2021)
30 Table 8: Gemtesa for IBS (November 24, 2020)
31 Table 9: Blautix for IBS (October 7, 2020)
33 Table 10: SYN-010 for IBS (October 2, 2020)
36 Table 11: Historical global sales, by drug ($m), 2017–21
37 Table 12: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Disease Analysis: Depression 
Sign up to the